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Introduction
Dendritic cells (DCs) comprise a heterogeneous group of  antigen-presenting cells (APCs) found throughout 
the body that include plasmacytoid DCs (pDCs) and CD11c myeloid DCs (mDCs) or conventional DCs 
(cDCs) (1). DC subsets display different cell surface markers that afford each specific DC population dif-
ferent functions (2). Consequently, normal immunity and tolerance are dependent on a balance among the 
DC subsets. In human skin, cDCs include epidermal Langerhans cells (LCs) and dermal CD1adimCD141–, 
dermal CD1adimCD141+, and dermal CD14+ subsets, which all have distinct functional properties (2–4). 
The dermal CD14+ DCs promote humoral immunity and regulate cellular immunity (5–10). In contrast, 
LCs enhance cellular immunity by inducing Th2 differentiation of  naive CD4+ T cells and via priming and 
cross-priming of  naive CD8+ T cells (5, 9, 11). Recently, human LCs were also shown to be responsible for 
directing IL-17– and IL-22–mediated responses (12–15), two responses indicative of  inflammatory autoim-
mune skin diseases, such as psoriasis.
Emerging studies demonstrate critical roles for the DC subsets in the initiation and maintenance of  
psoriasis (16, 17). These are supported by the increased numbers of  cytokine-producing DCs in psoriatic 
lesions and their role in inducing Th1 (IFN-γ, TNF-α, and Τh17 [IL-17 and IL-22]) responses (18, 19). 
Novel antipsoriatic therapies, which specifically target inflammatory DC cytokines, bring better clinical 
improvement compared with conventional treatments and implicate the crucial importance of  DCs in 
psoriasis pathogenesis (20, 21). Psoriatic inflammatory cDCs were described to include cells with reduced 
expression of  CD1c (18) and a subset of  DCs that produce TNF-α and iNOS (21). However, a detailed 
phenotype of  the key DC that contributes to the priming of  the inflammatory T cell response via Th1, 
Th17, or Th22 is still unknown (22).
Dendritic cells (DCs) are important in regulating immunity and tolerance and consist of functionally 
distinct subsets that differentially regulate T lymphocyte function. The underlying basis for 
this subset specificity is lacking, particularly in humans, where the classification of tissue DCs 
is currently incomplete. Examination of healthy human epidermal Langerhans cells and dermal 
skin cells revealed a tissue CD5-expressing DC subtype. The CD5+ DCs were potent inducers of 
cytotoxic T cells and Th22 cells. The products of these T cells, IL-22 and IFN-γ, play a key role in the 
pathogenesis of psoriasis. Remarkably, CD5+ DCs were significantly enriched in lesional psoriatic 
skin compared with distal tissues, suggesting their involvement in the disease. We show that CD5+ 
DCs can be differentiated from hematopoietic progenitor cells independently of the CD5– DCs. A 
progenitor population found in human cord blood and in the dermal skin layer, marked as CD34–
CD123+CD117dimCD45RA+, was an immediate precursor of these CD11c+CD1c+CD5+ DCs. Overall, our 
discovery of the CD5-expressing DC subtype suggests that strategies to regulate their composition 
or function in the skin will represent an innovative approach for the treatment of immune-mediated 
disorders in and beyond the skin.
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In this study, we extended the analysis of  all the DC populations in human skin and discovered that 
LCs and dermal DCs are heterogeneous, containing terminally differentiating DCs that express CD5. 
CD5+ DCs are superior activators of  inflammatory T cell responses. In addition, we revealed the pres-
ence of  pre-CD5 DC precursor in human dermis. These data offer insights into human tissue DC hetero-
geneity and ontogeny and highlight unexplored avenues for investigation of  the therapeutic potential of  
DC subset–specific targeting.
Results
CD5 marks a subset of  epidermal LCs and dermal CD1adim DCs in healthy skin. Human skin is known to contain 
four distinct mDC subsets. Three of  these, marked as CD1adimCD141−, CD1adimCD141+, or CD1a–CD14+, 
are found in the dermis, while CD1ahiLangerin+ LCs are found in the epidermis (3, 23). To define unique 
surface markers and to fully characterize expression patterns of  each epidermal and dermal subset, we 
performed a flow cytometry analysis of  332 different surface proteins. We found that both LCs and dermal 
CD1adimCD141– DCs are heterogeneous in 33 tested donors containing distinct CD5+ and CD5– popu-
lations (Figure 1, A and B). The CD5+ LCs fraction comprised a mean ± SEM of  6% ± 1.05% and the 
CD5+ DCs fraction in the dermis comprised 15.8% ± 2.1% of  skin DCs (Figure 1B). The CD5+ cells in 
both the epidermis and the dermis displayed DC morphology and were indistinguishable from their neg-
ative counterparts (Figure 1C). CD5 was not expressed on skin CD141-expressing cells, including dermal 
CD1adimCD141+ or dermal CD14+ DCs (Figure 1 A; right). The CD5+ cells in both epidermis and der-
mis expressed CD1c (Supplemental Figure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.96101DS1). Dermal CD5+ and CD5– cells but not epidermal CD5+ 
and CD5– cells expressed CD11b; conversely, only epidermal CD5+ and CD5– cells, but not dermal CD5+ 
and CD5– cells, expressed Langerin (Figure 1A, left, and Figure 1D). CD5 was also expressed on a subset of  
peripheral blood and cord blood CD11c+CD1c+ DCs but not on blood CD11c+CD141+ DCs (Supplemental 
Figure 1A). Skin CD5+ DCs expressed higher amounts of  CD83, CD86, and CCR7 than blood CD5+ DCs. 
However, the expression of  these markers was comparable to their skin CD5– DCs counterparts. Because 
CD5 and CD6 are often coexpressed on the surface of  T cells or B cells (24), the expression of  CD6 on the 
surface of  skin CD5+ DCs or skin-resident T cells was assessed. Interestingly, CD6 was absent from the sur-
face of  the DCs in the skin but was expressed on the surface of  skin-resident T cells (Supplemental Figure 
1B). This feature was shared with the blood CD1c+CD5+ DCs (Supplemental Figure 1C). Thus, CD5 marks 
a population of  human skin LCs and dermal CD1adim DCs.
CD5 marks a stable terminally differentiated DC subset. One indication of  whether CD5 demarcates a dis-
tinct cell fate of  DCs, rather than just constituting an activation marker, would be its stability on the surface 
of  a cell. Thus, the stability of  CD5 expression on the DC was tested in culture. Indeed, after 6 days in 
culture, CD5 was present on the surface of  CD5+ DCs and remained absent from the CD5– DCs (Figure 
1E, black histograms). To further assess whether CD5 marks a specific terminally differentiated cell fate, 
dermal CD5+ and CD5– DCs were exposed for 6 days to a variety of  stimuli, including Toll-like receptor 
(TLR-2, -3, -4) agonists, inflammatory or DC differentiating cytokines (IFN-γ, IFN-α, FLT3-L, granulocyte 
macrophage colony-stimulating factor [GM-CSF], IL-4), or a T cell signal (T cells, CD40L). Under these 
conditions, CD5 remained on the surface of  the positive cells and its level of  expression did not change sig-
nificantly (Figure 1E, top, red histograms). Moreover, CD5 expression was not detected on the stimulated 
CD5– DCs (Figure 1E, bottom, red histograms). Overall, these data demonstrate that CD5 marks a distinct 
and stable terminally differentiated DCs.
Dermal CD5+ DCs efficiently prime allogeneic naive CD8+ T cells. The biological properties of  CD5+ DCs 
from the dermis were first assessed by measuring their capacity to prime cytotoxic T lymphocyte (CTL) 
responses. Sorted live HLA-DR+CD1adimCD5+ DCs or their CD5– dermal counterparts were cocultured 
with allogeneic naive T cells and analyzed after 7 days for T cell proliferation. As shown in Figure 2, A 
and B, CD5+ DCs were more powerful stimulators of  naive CD8+ T cell proliferation than the CD5– DCs, 
as measured by the dilution of  CFSE. Consistent with previous reports, dermal CD1adimCD141+ and 
CD14+ DCs served as controls and induced only weak CTL responses (Figure 2, A and B) (5, 25). CD8+ 
T cells primed with CD5+ dermal CD1adim DCs expressed higher levels of  granzyme B compared with 
those primed with matched CD5– DCs (Figure 2, B and C). Moreover, we observed greater expansion 
of  IFN-γ– and TNF-α–producing CD8+ T cells by CD5+ dermal DCs, as measured intracellularly by 
flow cytometry (Figure 2D). Furthermore, CD8+ T cells that were primed by CD5+ dermal CD1adim DCs 
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produced more IFN-γ compared with the cells primed by the CD5– dermal CD1adim DCs, as measured in 
culture supernatant per cell (Figure 2E). Overall, our data show that the CD5+ DC subset is specialized in 
driving multifunctional CD8+ T cell immunity.
Dermal CD5+ DCs polarize naive CD4+ T cells into Th1 and Th22 cells. To address whether CD5+ DC pop-
ulations play a specific role in inducing the differentiation of  T helper cell subsets, we cocultured sorted 
dermal CD5+ or CD5– DCs with allogeneic naive T cells. After 6–8 days, dermal CD5+ DCs induced higher 
levels of  CFSE dilution compared with their CD5– counterparts (Figure 3A). Dermal CD14+ DCs and 
dermal CD1adimCD141+ DCs served as controls and were the weakest stimuli for proliferation (Figure 3A).
Figure 1. Identification of Langerhans cells and dermal DC subsets in human skin. (A) Top: Expression of CD1a and CD14 on purified skin DCs defines 
epidermal CD1a+ LCs, dermal CD1adim DCs, and dermal CD14+ DCs subpopulations. Bottom: Expression of CD5 defines subpopulations of CD1ahiLangerin+ 
LCs and dermal CD1adimCD141– DCs. (B) Relative representation of each human DC subset in normal skin (n = 33). The percentage of individual DC subsets 
mean ± SD ± SEM of the total migrating DCs (HLA-DR+CD3/19/56–) cells is plotted. Epidermal CD5+ LCs: 6.0% ± 6.15% ± 1.05%; CD5– LCs: 26.9% ± 20.4% 
± 3.4%; dermal CD1adim DCs, CD5+: 15.8% ± 12.6% ± 2.16%; CD5–: 37.6% ± 18.9% ± 3.2%; CD141+: 1.09% ± 2% ± 0.3%; dermal CD14+ DCs: 10.2% ± 7.6% ± 
1.3%. (C) Morphology of sorted skin CD5+ LCs, CD5– LCs, dermal CD1adimCD5+ DCs, CD1adimCD5– DCs, CD1adimCD141+ DCs, and CD14+ DCs visualized by GIEMSA 
staining. Scale bar: 10 μM. (D) HLA-DR+CD11c+CD14–CD1c+CD5+ and CD5– DCs from skin epidermis, dermis, blood, and in vitro–differentiated cultures were 
analyzed for the expression of CD1a, CD11b, Langerin, CD83, CD86, CCR7, and HLA-DR. The plot shows GeoMean intensity, with values of the background 
staining subtracted. The mean values obtained for 2–4 donors are plotted. (E) Dermal CD1adimCD5+ and CD5– DCs were sorted and stimulated as indicated. 
Histograms show expression of CD5 on the cells after 6 days of stimulation (red histograms). One representative of 3 donors is shown.
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Subsequently, the capacity of  DCs to polarize CD4+ T cells was examined by measuring their cytokine 
production. Dermal CD5+ DCs induced a significant difference in the proportion of  polarized IL-22–express-
ing T cells when compared with CD5– DCs or those primed by CD14+ DCs (Figure 3, B and C). In addition, 
the amount of  IL-22 produced by each T cell was higher in cells primed by dermal CD5+ DCs compared with 
those primed by dermal CD5– DCs (Figure 3D, top). Although both CD5+ and CD5– DCs could polarize 
IFN-γ–producing CD4+ T cells, CD5+ DCs were more efficient in this process (Figure 3, C and D, bottom). 
Figure 2. Dermal CD5+ DCs are more efficient than their CD5– counterparts at priming CTLs. (A) Allogeneic naive CD8+ T cells primed with sorted 
CD40L-activated skin dermal CD5+ or CD5– CD1adim DCs, dermal CD1adimCD141+ DCs, or dermal CD14+ DCs at ratio 1:40 for 7 days. The graph shows the percent-
age of proliferating (CFSElo) CD3+CD8+ T cells (n = 15). Mean ± SD ± SEM for CD5+: 53.7% ± 26.6% ± 6.8%, CD5–: 36.4% ± 20.7% ± 5.3%, CD141+ DCs: 20.2% 
± 16.1% ± 5.3%, CD14+ DCs: 15.1% ± 17% ± 5.6%. (B) Allogeneic CFSE-labeled naive CD8+ T cells primed for 7 days by each dermal skin mDC subset were 
stained and analyzed by flow cytometry for the expression of granzyme B. The percentage of cells that diluted CFSE and expressed granzyme B is shown. 
One of 8 experiments is shown. (C) The plot shows the percentage of cells primed by each of the mDC subsets and expressed granzyme B (n = 8). (D) The 
plots show the expression of IFN-γ and TNF-α by naive CD8+ T cells that were primed by either dermal CD5+ or CD5– DCs. CD8+ T cells primed by the dermal 
CD14+ DCs are shown as a control. One of 5 experiments is shown. (E) CFSEloCD8+ T cells that were primed by either dermal CD1adimCD5+ or CD5– DCs were 
reactivated by anti-CD3 and anti-CD28 mAbs for 18 hours. IFN-γ was measured in the culture supernatant by a Luminex magnetic bead assay. The graph 
shows the pooled results of 4 experiments. Data represent mean ± SEM; **P < 0.01, ****P < 0.0001 by paired Student’s t tests (A, C, and E).
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Thus, dermal CD5+ DCs are more efficient than CD5– DCs in inducing the proliferation and polarization of  
naive CD4+ T cells into IFN-γ and IL-22 cytokine–secreting cells.
Functional analysis of  CD5+ and CD5– LCs. Since we also found that a subset of  LCs expressed CD5, we 
assessed their capacity to activate allogeneic naive CD8+ and CD4+ T cell responses. Live HLA-DR+C-
D1ahiCD5+ and CD5– LCs were cocultured with allogeneic naive T cells and analyzed after 7 days for T 
cell proliferation. Consistent with the findings obtained using dermal CD5+ and CD5– DCs, we found that 
CD5+ LC subsets were more efficient than the CD5– LCs at inducing allogeneic CD8+ T cell proliferation 
(Figure 4A). The number of  granzyme B–producing primed CD8+ T cells (Figure 4, B and C), as well as 
Figure 3. Dermal CD5+ DCs are superior to dermal CD5– DCs at inducing the proliferation and differentiation of Th22 cells. (A) Proliferation of allogeneic 
naive CD4+ T cells primed with sorted CD40L-activated dermal CD5+ or CD5– CD1adim DCs, dermal CD1adimCD141+, or dermal CD14+ DCs was measured after 
7 days by CFSE dilution using flow cytometry. The graph shows the frequency of the CFSEloCD3+CD4+ T cells (n = 10). Mean ± SD ± SEM for CD5+: 39.5% ± 
19.8% ± 6.6%, CD5–: 22.9% ± 17% ± 7.6%, CD141+ DCs: 19.5% ± 17% ± 7.6%, CD14+ DCs: 5% ± 4.4% ± 1.65%. (B) CFSE-labeled sorted naive CD4+ T cells cul-
tured for 6 days with CD40L-activated dermal CD1adimCD5+ or CD1adimCD5– DCs. CFSE dilution and cytoplasmic expression of IFN-γ and IL-22 were analyzed 
by flow cytometry after 5-hour stimulation with PMA and ionomycin. (C) The plot shows the frequency of IL-22–producing CD4+ T cells that were primed 
by the different skin DC subsets (n = 10). Top: The plot shows the frequency CD4+ T cells that diluted CFSE and express IL-22. Bottom: The plot shows 
the frequency of IFN-γ and IL-22–producing CFSEloCD4+ T cells. Data are representative of 7 independent experiments. (D) CFSEloCD4+ T cells, primed by 
either dermal CD1adimCD5+ or CD5– DCs, were sorted and restimulated with anti-CD3 and anti-CD28 mAbs for 18 hours. IL-22 and IFN-γ were measured by 
a Luminex multiplex bead assay (n = 3). One of 3 experiments is shown. Data represent mean ± SEM; **P < 0.01, ***P < 0.005, ****P < 0.0001 by paired 
Student’s t tests (A and C) or unpaired Student’s t tests (D).
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the number of  multifunctional IFN-γ– and TNF-α–producing CD8+ T cells (Figure 4D), was higher in 
cultures primed by the CD5+ LCs compared with the CD5– LCs. We found that the CD5+ LC subset was 
also more efficient at inducing allogeneic CD4+ T cell proliferation than CD5– LCs (Figure 4E) as well as 
in the differentiation of  CD4+ T cells that produced IL-22 (Figure 4F). Overall, CD5 expression on LCs 
further potentiates their capacity to prime CTLs and Th22 cells.
CD5+ DCs are enriched in the epidermis and the dermis of  psoriasis patients. Given the ability of  skin CD5+ 
DCs to activate Th1 and Th22 cells, the hallmark response in the pathogenesis of  psoriasis, we next assessed 
Figure 4. Functional characterization of CD5+ and CD5– LC subsets. (A) The percentage of CFSElo allogeneic naive CD8+ T cells that were primed for 6–8 
days by sorted activated CD5+ and CD5– LCs. Results of 10 independent experiments are shown. Mean ± SD ± SEM CD5+ LCs: 56.4% ± 21.2% ± 6.7%; 
CD5– LCs: 46.8% ± 20.1% ± 6.3%. (B) Allogeneic CFSE-labeled naive CD8+ T cells primed for 7 days by each LC subset were stained and analyzed by flow 
cytometry for the expression of granzyme B. The percentage of cells that diluted CFSE and expressed granzyme B is shown. One of 8 experiments is 
shown. (C) The plot shows the percentage of cells primed by each of the mDC subsets and expressed granzyme B (n = 8). (D) The plots show the expres-
sion of IFN-γ and TNF-α by naive CD8+ T cells that were primed by either CD5+ or CD5– LCs. One of 3 experiments is shown. (E) The percentage of CFSElo 
allogeneic naive CD4+ T cells that were primed for 6–8 days by sorted activated CD5+ or CD5– LCs (n = 9). Mean ± SD ± SEM CD5+ LCs: 71.7% ± 22.3% ± 
7.4%; CD5– LCs: 54.5% ± 31.4% ± 10.5%. (F) CFSE-labeled sorted naive CD4+ T cells cultured for 6 days with CD40L-activated CD5+ LCs or CD5– LCs. The 
plot shows the frequency of IL-22–producing CD4+ T cells that were primed by the different LC subsets (n = 10). Data represent mean ± SEM; *P < 0.05 
(A, C, and F), **P < 0.01 (E) by paired Student’s t tests.
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their involvement in the disease. Skin biopsies were obtained from involved psoriatic plaques and adjacent 
nonlesional skin (uninvolved) from patients with psoriasis. Dermal and epidermal DCs were purified in a 
similar manner to that with healthy skin and analyzed by flow cytometry. The frequency of  CD5+ DCs in 
both the dermis and the epidermis was found to be 2-fold higher in the psoriatic skin plaque as compared 
Figure 5. CD5+ LCs and dermal DCs are increased in psoriatic lesions compared with nonlesional psoriatic skin. (A) Expression of CD5 and CD14 on 
epidermal and dermal DCs from uninvolved (left arm) and involved (left forearm) lesions of psoriasis patient 025 (see Table 1). (B) The percentage of 
CD5+ DCs in the epidermis (left) and dermis (right) of uninvolved and involved skin lesions of 7 and 8 patients, respectively. The percentage of the total 
migrating DCs (HLA-DR+CD3/19/56–) cells. Mean ± SEM: epidermal CD5+ DCs, uninvolved, 23.4% ± 4.6%; involved, 35.7% ± 4.7%; dermal CD5+ DCs, 
uninvolved, 32.7% ± 5.2%; involved, 52.2% ± 7.8%. Dashed lines mark the levels of CD5+ DCs in healthy skin. Data represent mean ± SEM; **P < 0.01 
by paired Student’s t tests. (C) Immunofluorescence staining of CD5 and CD1a on healthy skin and psoriasis uninvolved and involved skin. Scale bar: 
100 μM. (D) CD5 and CD1a expression in psoriasis, cutaneous lupus, Langerhans cell histiocytosis (LCH), and graft-versus-host diseased (GvHD) skin. 
Original magnification, ×20 (top); ×40 (bottom).
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with the nonlesional skin in all patients examined (Figure 5, A and B). Interestingly, the uninvolved skin 
presented with higher amounts of  CD5+ DCs compared with healthy skin by an average of  1.6 times (Fig-
ure 1B and Figure 5, B and C). The CD5+ DCs seen in the epidermis expressed lower amounts of  CD1a 
(Supplemental Figure 2), suggesting that they might be newly differentiated bone marrow cells that migrated 
to the epidermis or dermal DCs that migrated to the epidermis. Increased numbers of  CD5+ DCs, as mea-
sured by the coexpression of  CD1a and CD5, were also observed in the epidermis and dermis in situ, using 
tissue immunostaining (Figure 5, C and D). In contrast with cutaneous lupus, in which high amounts of  
CD1a–CD5+ cells were found, and LC histocytosis skin, which predominantly contained CD1a+CD5– cells, 
skin of  a graft-versus-host patient contained CD1a+CD5+ LCs, which were the only cell type detected in this 
patient (Figure 5D), suggesting their contribution to this inflammatory skin condition and consistent with 
the greater capacity of  the CD5+ DCs to induce allogeneic CD8+ and CD4+ T cell responses (Figure 4, A 
and E). Overall, our data suggest that CD5+ DCs could play a key role in exacerbating the pathogenesis of  
psoriasis by promoting CTLs and inflammatory helper T cell responses.
CD34+ hematopoietic progenitors give rise to CD1c+CD5+ DCs. To define the developmental relationship between 
the CD5+ and the CD5– subset, CD34+CD117+ hematopoietic progenitor cells (HPCs) from cord blood were 
differentiated into DCs on the mouse stromal cell line, MS-5, and in the presence of the cytokines, GM-CSF, 
stem cell factor (SCF), and FLT3 ligand (FLT3-L), as previously described (5, 26–28). The expression of CD5 
was detected on the differentiated CD1c+ DCs after 7 days (Figure 6, A and B). These results were consistent 
with the characterization of skin DCs, in which the CD5+ DCs branch out as a subset of the CD1c+CD1ahi 
DCs in the epidermis (LCs) and CD1c+CD1adim DCs in the dermis (ref. 5, Figure 1A, and Supplemental Figure 
1A). CD11b expression was shared between the in vitro CD5+ DCs and dermal CD5+ DCs (Figure 1D). Lan-
gerin was only expressed on a small fraction of the in vitro CD1a+ DCs and by LCs (Figure 1D). In vitro CD5+ 
DCs expressed lower levels of the activation markers CD83, CD86, and CCR7 than skin DCs but higher levels 
than those expressed by blood CD5+ DCs. (Figure 1D). Functionally, similar to their ex vivo counterparts, in 
vitro CD5+ DCs were also more efficient than the CD5– DCs or CD14+ DCs at inducing the proliferation of  
allogeneic CD8+ T cells (Figure 6C) and priming CD8+ T cells to differentiate into CTLs that produced gran-
zyme B and perforin (Figure 6D) as well as IFN-γ and TNF-α (Figure 6E). Moreover, CD5+ DCs that differen-
tiated from CD34+ HPCs were more efficient than the CD5– DCs or CD14+ DCs at inducing the proliferation 
of allogeneic CD4+ T cells and priming CD4+ T cells to differentiate into IL-22–producing cells (Figure 6, F 
and G). In addition, the amount of IL-22 produced per cell was higher in T cells that were primed by in vitro 
CD5+ DCs compared with those primed by in vitro CD5– DCs (Figure 6H) Thus, CD5+ DCs develop from 
bone marrow independently of the CD5– fraction and resemble their ex vivo counterparts.
TNF signaling enhances the development of  CD5+ DCs from CD34+ hematopoietic progenitors. Next, we assessed 
whether the differentiation of  CD5+ DCs would be altered in the presence of  cytokines that are abundant 
in inflamed psoriatic skin, such as TNF-α and lymphotoxin α/β (LTα/β). Indeed, we found that addition of  
Table 1. Demographic data of psoriasis patients studied
Patient ID Sex Age Involved tissue Uninvolved tissue Treatments (previous and current) Type
PS001 Male 62 Unspecified Unspecified Unspecified Plaque
PS004 Male 70 Buttock Buttock Unspecified Plaque
PS005 Female 50 Left leg Right arm Humira, clobetasol ointment, methotrexate Plaque
PS007 Female 76 Left buttock Left back Topical steroids and Enbrel Plaque
PS011 Female 57 Right forearm Right lower back NBUVB, MTX, topicals, Humira, Taclonex Plaque
PS012 Male 58 Right elbow Right upper arm NBUVB, Humira, MTX, clobetasol, triamcinalone Plaque
PS013 Female 47 Right forearm Left upper elbow Triamcinolone Plaque
PS016 Male 33 Left forearm Left arm Topical steroids Plaque




Methotrexate, Humira Chronic plaque and 
guttate
PS018 Female 76 Posterior neck Right inner arm Taclonex ointment (dexamethasone, Dovonex) Plaque
PS019 Female 46 Right elbow Right upper arm Topical steroids and Enbrel Plaque
PS025 Female 65 Left lateral lower leg Topical steroids Plaque
PS026 Female 80 Scalp and face No previous treatment Plaque
Psoriasis patient information, including sex, age, anatomical location of the involved and uninvolved biopsy specimens, treatment history, and type.
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TNF-α or LTα/β to GM-CSF, SCF, and FLT3-L promoted the differentiation of  the CD11c+CD1c+CD5+ 
DCs (Figure 6B and Supplemental Figure 3B). The number of  CD5+ DCs measured on day 7 increased from 
0.42 × 103 ± 0.4 × 103 cells/ml with GM-CSF, SCF, and FLT3-L to 5.31 × 103 ± 3.7 × 103 cells/ml with 
addition of  TNF-α and 2.78 × 103 ± 0.4 × 103 cells/ml with the addition of  LTα/β (Figure 6B). The ability 
Figure 6. CD5 marks a functional terminally differentiated DC subset. (A) The plots show the frequency of CD11c+CD1a+CD5+ and CD11c+CD1c+CD5+ DCs obtained 
from cultures of cord blood CD34+CD117+CD123– cells with GM-CSF (GM), SCF, and FLT3-L (FL) on day 7. (B) The graph shows the number of CD11c+CD1c+CD5+ DCs 
on day 7 of culturing CD34+ HPCs with indicated cytokines (n = 6). (C) Day 12 in vitro CD1c+CD5+, CD1c+CD5–, or CD14+ DCs were sorted and cocultured with naive 
T cells. The graph shows the number of CD8+ T cells that diluted CFSE in response to different DC subsets from the different culture conditions. (D) Sorted in 
vitro DC subsets were cocultured with naive allogeneic CFSE-labeled T cells for 7 days (300 DCs: 1 × 105 T cells). CFSElo cells were analyzed for the expression of 
granzyme B and perforin. One of three experiments is shown. (E) Similar to D, the plot shows the expression of IFN-γ and TNF-α by naive CD8+ T cells that were 
primed by each in vitro DC subsets. One of 3 experiments is shown. (F) Similar to C, the graph shows the number of CD4+ T cells that diluted CFSE in response 
to different to different DC subsets from the different culture conditions. (G) Similar to D, the plot shows the fraction of CD4+ T cells that diluted CFSE and 
produced IL-22 following 6 days of priming with the different DCs subsets. One of 3 experiments is shown. (H) The plot shows IL-22 and IFN-γ production by 
CFSEloCD4+ T cells that were primed by each in vitro DC following reactivation by anti-CD3 and anti-CD28 mAbs for 18 hours (n = 6 for CD5+ and CD5–; n = 3 for 
CD14+ DCs). Data represent mean ± SEM (B, C, F, and H); *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001 by paired Student’s t tests.
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.96101
R E S E A R C H  A R T I C L E
of  the CD5+ DCs to expand allogeneic CD4+ and CD8+ T cells was higher than that of  CD5– DCs and 
CD14+ DCs, regardless of  whether the cells were cultured in the presence of  TNF-α or LTα/β (Figure 6, C 
and F). Overall, CD5+ DCs branch out from the CD1c+ DCs and their differentiation potential is enhanced 
by TNF-α signaling, including TNF-α and LTα/β.
CD34–CD123+CD117dimCD45RA+ cells are an immediate precursor to human CD5+ DCs. The fact that only a 
fraction of  CD34+ HPCs differentiated into CD5+ DCs led us to hypothesize that a committed progenitor 
Figure 7. CD34–CD123+CD117dimCD45RA+ cells preferentially give rise to CD5+ DCs. (A) Gating strategy for cord blood progenitors. Cells were sorted as Lin–
DC–CD10–CD123– (see also Supplemental Figure 3): CD34+CD117+ (blue); CD34–CD117+ (orange); or Lin–DC–CD10–CD123+CD34–CD117dimCD45RA+ (red). Histograms 
show the expression of CD5 and CD45RA on the different progenitor subsets. Expression on lineage+ cells is shown as a control (gray). (B) Sorted cord 
blood CD34+CD123–CD117+, CD34−CD123–CD117–, or CD34−CD123+CD117dim progenitors were cultured in the presence of GM-CSF, SCF, FLT3-L, and LTα/β. Flow 
cytometry plots, gated on live CD45+HLA-DR+CD11c+ cells, show culture output of CD1a+CD5+ DCs on day 7. Representative results of 4 independent exper-
iments are shown. (C) Gating strategy for dermal progenitors. Cells were sorted as Lin–DC–CD10– that were CD34+CD123–CD117– (blue); CD34–CD123–CD117+ 
(orange); or CD34−CD123+CD117dim (red). Histograms show the expression of CD5 and CD45RA on the different progenitor subsets. (D) CD34+CD123–CD117–, 
CD34−CD123–CD117+, or CD34−CD123+CD117dim were isolated from human dermis. Flow cytometry plots are gated on live CD45+HLA-DR+CD11c+ cells and show 
the expression of HLA-DR+ or lineage+ cells that were differentiated from the different progenitors. (E) The plots show the expression of CD1c and CD5 on 
HLA-DR+ cells that differentiated from CD34−CD123+CD117dim cells for 7 days in the presence of in the presence of GM-CSF (GM), SCF, and FLT3-L (FL) and 
either TNF-α or LTα/β. Representative results of 3 independent experiments are shown.
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for CD5+ DCs might exist in the bone marrow. Thus, we assessed whether CD5+ DCs would differentiate 
from the recently identified DC precursors (pre-cDC), CD34– progenitors (27, 28). Progenitors were sorted 
from cord blood as lineage–(CD3/19/56/14/66b)DC–(CD1c/141/303)CD10–CD123– cells that were either 
CD34+CD117+ (GMDPs/MDPs) or CD34–CD117+ (pre-cDC) (Figure 7A) and cultured for 7 days on 
MS-5 cells with GM-CSF, SCF, FLT3-L, and LTα/β. Indeed, both CD11c+CD1a+CD5+ and the CD11c+C-
D1a+CD5– DCs differentiated from the CD34+CD117+ or the CD34–CD117+ DC progenitors (Figure 7B). 
We noticed, however, a third progenitor population within the CD34– lineage(CD3/19/56/14/66b)–DC(C-
D1c/141/303)–CD10– population that was marked by CD123+ and low levels of  CD117 and expressed 
CD45RA (Figure 7A, red). Surprisingly, we found that under similar culture conditions, these cells prefer-
entially differentiated into CD11c+CD1a+CD5+ DCs (Figure 7B). Thus, the high clonal efficiency and dif-
ferentiation potential of  the CD34–123+CD117dimCD45RA+ progenitor cell suggests that it could represent 
a committed progenitor for the CD5+ DCs.
CD34–CD123+CD117dim progenitors are found in human dermis and give rise to CD5+ DCs. We next assessed 
whether this progenitor population is present in skin. Thus, cells were isolated from epidermis and dermis 
and analyzed for the presence of  progenitors in a similar manner to the cord blood within the lineage(C-
D3/19/56/14/66b)–DC(CD1c/141/303)–CD10– population. Within the CD123– fraction of  the dermis, 
but not epidermis, we found a population of  CD34+ HPCs as well as CD34–CD117+ cells. However, in 
contrast with cord blood, dermal CD34+ cells did not express CD117 (Figure 7, A and C, blue gate).
Similar to cord blood, we found a population marked by CD123 that expressed low levels of  CD117 
(Figure 7C, red gate); however, compared with the cord blood CD123+ progenitors, which were negative 
for CD5 and expressed CD45RA (Figure 7A, red histograms), the dermal CD123+ population expressed 
low levels of  CD5 and lower levels of  CD45RA (Figure 7C, red histograms). Sorted progenitors were 
cultured on mouse stromal cells in the presence of  cytokines for 7 days. As shown in Figure 7D, dermal 
CD34+ HPCs gave rise to 20% HLA-DR+ cells and 2% lymphoid cells (CD3/CD19/CD56), and dermal 
CD34–CD123–CD117+ gave rise primarily to lymphoid cells (85.2%). The CD34–CD123+CD117dim HPCs 
gave rise primarily to HLA-DR+ cells (82.6%), and the majority of  these cells expressed CD1c and CD5 
(Figure 7E). The differentiation of  the CD1c+CD5+ DCs occurred in the presence or absence of  LTα/β or 
TNF-α (Figure 7E). Thus, a progenitor for the CD1c+CD5+ DCs is present in human dermis.
Discussion
Here, we have further unraveled the complexity of  the human skin DC system and its progenitor cells in 
the dermis. We show that CD5 marks a terminally differentiated inflammatory DC subset. Its presence 
in the epidermis highlights a previously unappreciated heterogeneity within human LCs, which has been 
previously noted in the mouse (29). The presence of  the CD5+ DCs at early stages of  the immune system 
development, i.e., in cord blood, which has never been exposed to a foreign antigen, further supports our 
hypothesis that CD5 demarks what we believe to be a unique subset rather than an activation state.
In addition to elevated levels of  the inflammatory CD5+ DCs in psoriatic plaques, we also observed 
that CD5+ LCs (as detected by the expression of  CD5 and CD1a) were the only epidermal DCs in acute 
graft-versus-host disease patient skin, suggesting their involvement in both of  these inflammatory diseases. 
Indeed, genome-wide association studies revealed a pathogenic relevance for CD5 in inflammatory bowel 
disease (IBD) (30), multiple sclerosis (31), and rheumatoid arthritis (RA) (32). Similar to psoriasis, Th22 
cells and plasma IL-22 levels play a detrimental role in RA. Since CD5+ DCs are potent activators of  Th22 
response, a therapy that specifically targets CD5+ DCs to prevent Th22 cell induction and reduce IL-22 lev-
els might ameliorate symptoms of  both of  these diseases (33). On the other hand, IL-22 plays crucial roles 
in regulating barrier immunity and antimicrobiota (34) and can potentially protect patients with ulcerative 
colitis (UC), a form of  IBD in which IL-22–producing cells are reduced in the gut (35). Therefore, harness-
ing CD5+ DCs to restore Th22 cells to the intestinal mucosa during active inflammation may be an avenue 
for novel therapeutics against UC. Interestingly, Crohn’s disease, which is another form of  IBD, is charac-
terized by elevated levels of  Th17 cytokines (IL-17 and IL-22); this points to the possibility that CD5+ DCs 
could serve as a biomarker to distinguish between these two very different forms of  IBD. Future studies will 
be important to understand the role of  CD5 on DCs in these pathological conditions.
Several possible mechanisms might account for the ability of  CD5 on DCs in mediating these robust 
T cell responses. Although there is no confirmed ligand for CD5, a recent study suggests that CD5 may be 
homophilic, binding CD5 on the surface of  other cells (36). In addition, it was also shown that the ligation 
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of CD5 on T cells results in the polarization of  naive T cells into the Th17 pathway (37), and, more recently, 
in the mouse, a CD5-like molecule (CD5L) was shown to regulate the pathogenicity of  Th17 (38, 39). Thus, 
we surmised that CD5 on DCs might bind to CD5 (or CD5L) on T cells, resulting in effector T cell polariza-
tion. Initial assessment of  the role of  CD5 costimulation on DCs by using a monoclonal antibody to CD5 
during a coculture led to increased T cell activation, suggesting that ligation of  CD5 on DCs may deliver a 
positive signal or promote their activation. Interestingly, a study that was relatively overlooked showed that 
CD5 recognizes the fungal cell wall component, zymosan (40). Thus, it is also possible that CD5 expression 
on DCs serves as a pattern recognition receptor and mediates the production of  proinflammatory cytokines 
upon activation. This is intriguing, as none of  the other known receptors for zymosan (i.e., TLR-2 or dectin-1) 
are present on CD5+ LCs and dermal CD1adimCD5+ DCs; however, they are highly abundant on the dermal 
CD14+ DCs (25). Whether CD5 recognizes other pathogen-associated molecular patterns besides zymosan 
remains to be established. Overall, the rapid proliferation and T cell differentiation mediated by CD5+ DCs 
led us to propose that these DCs may be prone to respond faster to a foreign antigen and that CD5 might facil-
itate the recognition of  a danger signal. If  this hypothesis is true, this functionality of  the CD5+ DCs could be 
advantageous, particularly in the skin, which serves as the first line of  defense against pathogens. Moreover, 
as a scavenger receptor, CD5 may plausibly serve as an uptake or a pathogen clearance receptor to mediate 
cross-presentation of  dead cell-associated proteins by DCs and activation of  antigen-specific CD8+ T cells, 
similar to Clec9A (41, 42), which has restricted expression to CD141+ DCs in humans. In addition, since 
CD5 expression is restricted to the CD1a+CD1c+ DCs, it might even mediate the presentation of  lipids onto 
nonclassical MHC class I and the priming of  CD1a-restricted Th22, as seen in patients with psoriasis (14, 43).
We have noticed that the differences between the dermal CD5+ and the CD5– DCs in priming alloge-
neic T cell responses (Figure 2A and Figure 3A) were greater than those between CD5+ LCs and CD5– 
LCs (Figure 4, A and E). As previously reported, LCs are highly effective initiators of  allogeneic T cell 
responses (5, 9, 44) and thus, limiting culture conditions (i.e., high DC/T cell ratio, low IL-2) permitted us 
to reveal the contribution of  CD5 to the outcome of  the T cell responses. We envision that CD5+ LCs will 
be particularly efficient at priming an antigen-specific response where the T cell precursor frequency is low 
or when the antigen is of  low affinity, like those that are expressed in tumors.
The developmental stages of  human DCs are still incompletely defined. We show that, once differ-
entiated, dermal CD1c+CD5– DCs (Figure 1E), but also CD5– LCs (data not shown), would not upregu-
late CD5 upon activation, suggesting that CD5 does not represent an activation marker. Our tested DC 
activators in this assay, however, do not exhaust the possibility that within the skin microenvironment, in 
response to a pathogen or a chronic condition, CD5 expression could be modulated on the DCs. Neverthe-
less, the presence of  CD5+ DCs in cord blood (Supplemental Figure 1A), which has never been exposed 
to a foreign antigen, further supports our hypothesis that CD5 demarked a unique subset. We show that 
CD5+ DCs can be differentiated from human CD34+ HPCs isolated from cord blood and from a pre-cDC 
progenitors CD34–CD117+ cells (26). The differentiated CD5+ cells represented a subset of  the CD1a+C-
D1c+ DCs and the CD1adim or negCD1c+ DCs. The former may be similar to the CD1ahiCD1c+CD5+ LCs, 
while the latter may be similar to the blood CD1c+ DCs and to the dermal CD1adimCD1c+ DCs. Consis-
tent with our findings, FLT3 was shown in patients to induce the generation of  CD5-expressing blood 
DCs (45), and functionally, the CD1c+CD5+ DCs in the blood appear to share the superior capacity for 
enhancing CD4+ T cell proliferation (46), as we found with the skin and in vitro–differentiated CD5+ DCs. 
Our study identified a progenitor marked as CD34–CD123+ cells in cord blood and in human dermis that 
gave rise primarily to the CD11c+CD1c+CD5+ DCs, which we referred to as “pre-CD5+ DCs.” Pre-cDCs 
were initially found in humans within the CD34–CD123– fractions (28); however, a recent study reported 
the presence of  CD123hiCD33+CD45RA+CD303+ pre-DCs in peripheral blood (47). In contrast with See 
et al., our gating strategy excluded all the cells that expressed the pDC marker CD303/BDCA-2; thus, 
perhaps we looked at a distinct, possibly more committed, pre-cDC subset. Whether the CD123hiCD33+C-
D45RA+ precursors identified in that study can be differentiated into CD5+ DCs was not tested; however, 
they were reported to express CD5. Two additional studies identified CD123+ DC populations in periph-
eral blood that are within the pDC gate and also express CD5, one that is a subset of  pDC (48) and the 
other referred to as “AS DCs,” expressing Axl and Siglec6 (49). The latter were able to transition toward 
the CD1c+ DC state in vitro with superior capacity to activate T cells; however, the authors claim that 
these cells are less likely to be progenitors. Single-cell profiling studies are needed to determine whether 
and how these CD123+ precursors and CD123+ DCs are related.
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We found that TNF-R signaling (including TNF-α and LTα/β) promoted the differentiation of  uncom-
mitted pre-DCs into CD1c+CD5+ DCs. In the mouse, lymphotoxin-β receptor signaling was required for 
the differentiation step of  a subset of  the CD11b+ DCs expressing high amounts of  ESAM (50). Interest-
ingly, blood CD1c+CD5+ DCs were recently shown to share a genetic signature with the ESAMhi mouse 
DC population (46). Thus, conceivably, exposure of  dermal progenitors (CD123+CD117dim) to LTα/β in 
the skin might make them prone to develop into the CD5+ DC subset, rendering them a potent source of  
inflammatory CD5+ DCs, ready for rapid mobilization and T cell activation. However, unabated induction 
of  CD5+ DCs from dermal progenitors by excess amounts of  TNF-α and LTα/β may drive the autoimmune 
response in psoriasis. Ultimately, defining the mechanisms that maintain these cells in their initial uncom-
mitted state in health and disease could lead to the development of  new therapeutic strategies to modulate 
this differentiation process.
We were limited from using a mouse model for psoriatic disease in this study due to the global expres-
sion of  CD5 in the mouse. CD5 is expressed on lymphocytes and DCs; thus, a global knockout for CD5 
would not provide a definitive answer for the role of  CD5 expression on each cell type in the disease. 
Future studies should attempt to generate a mouse with a specific deletion of  CD5 on DCs to be used in 
a disease model. Furthermore, it is not known whether the function of  mouse and human CD5+ DCs is 
similar. A recent study by Artyomov and Munk et al. (25) showed that human and mouse DCs that are 
similar anatomically and, in fact, may have different functions. This may add to the complexity of  study-
ing a disease such as psoriasis, which is only transient in current rodent models but chronically affects 
millions of  humans.
Overall, we envision that mobilization of  CD5+ DCs will be beneficial in vaccination where CTL 
induction is desired, such as in cancer. On the other hand, strategies to regulate CD5+ DC composition or 
function will represent an innovative approach for the treatment of  psoriasis and other immune-mediated 
disorders in and beyond the skin.
Methods
Skin and blood specimens. Healthy human skin was obtained from donors who underwent cosmetic and 
plastic surgeries at Washington University School of  Medicine in St. Louis and Barnes-Jewish Hospital (St. 
Louis, Missouri, USA) in accordance with institutional review board guidelines. Psoriatic plaque biopsy 
samples or whole-blood samples were acquired at Barnes-Jewish West County Hospital (St. Louis, Missou-
ri, USA) in accordance with institutional review board guidelines. Lupus, LC histiocytosis, and graft-ver-
sus-host disease skin specimens were obtained from the Dermatopathology Center at Washington Univer-
sity School of  Medicine in St. Louis. Patient and specimen characteristics are listed in Table 1.
DC isolation. Skin DC subsets were isolated as described previously (5). Briefly, tissue specimens were 
incubated with the bacterial protease, Dispase type II (Roche), for 18 hours at 4°C. Epidermal and dermal 
sheets were then separated and placed in RPMI 1640 (Gibco) supplemented with 10% fetal bovine serum 
(GemCell) and incubated for 48 hours at 37°C. The cells that migrated into the medium were enriched 
using a Ficoll-diatrizoate gradient, Lymphocyte Separation Medium (MP Biomedicals). DCs were stained 
using the antibodies listed in Supplemental Table 1 and were further purified by cell sorting using a BD 
FACSAria II. HLA-DR+CD3–CD19– DCs subsets are marked in the epidermis as CD1ahiLangerin+CD5+ 
or CD1ahiLangerin+CD5–. In the dermis, the four DC subsets are marked as CD1adimCD141–CD5+, CD1ad-
imCD141–CD5–, CD1adimCD141+, or CD14+ DCs. CD40L (100 ng/ml; R&D Systems) was used to activate 
DCs. The stability of  CD5 expression on skin DCs was assessed by culturing sorted CD5+ or CD5– DCs 
from the dermis with indicated DC activators for a period of  6 days. The expression of  CD5 was analyzed 
by flow cytometry.
Human CD34+ HPCs and CD34– pre-DCs isolation and differentiation. Cord blood samples were pur-
chased from the St. Louis Cord Blood Bank and processed according to protocols approved by the 
Institutional Review Board at the Washington University School of  Medicine in St. Louis. Imme-
diately upon sample arrival, the cord blood was incubated with RosetteSep Human Hematopoietic 
Progenitor Cells Enrichment Cocktail (StemCell) to deplete CD2, CD3, CD14, CD16, CD19, CD24, 
CD56, CD61, and CD66b from the cord blood. Further, mononuclear cells were isolated by Ficoll-di-
atrizoate density gradient centrifugation, using Ficoll-Paque PLUS (GE Healthcare Life Sciences) at 
800 g, for 30 minutes. CD34+ HPCs were isolated from cord blood mononuclear cells through pos-
itive selection using the EasySep Human CD34 Positive Selection Kit (StemCell Technologies) or 
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Miltenyi Biotec CD34+ microbeads or were labeled with an antibody mix (Supplemental Table 1) 
and sorted using a BD AriaII. Cord blood progenitor cells were sorted as live Lin–(CD1c, CD141, 
BDCA2)–CD10– that were also CD34+CD123–CD117+, CD34–CD123–CD117+, or CD34–CD123+CD-
117dimCD45RA+. Dermal progenitor cells were sorted as live Lin–(CD1c, CD141, BDCA2)–CD10– that 
were also CD34+CD123–CD117–, CD34–CD123–CD117+, or CD34–CD123+CD117dim. Progenitors 
were cultured as described previously (26). Briefly, MS-5 stromal cells (a gift from Kang Liu, Columbia 
University, New York, New York, USA) were maintained in complete α-Minimum Essential Medium 
(αMEM) media supplemented with L-glutamine, but without ribonucleosides and deoxyribonucleo-
sides (Invitrogen) and with 10% heat-inactivated fetal calf  serum (GemCell) and 1% penicillin/strep-
tomycin (Invitrogen). 24 hours prior to coculture with HPCs, stromal cells were treated with 10 μg/ml 
Mitomycin C (Sigma-Aldrich) for 3 hours at 37°C and plated at 2.5 × 104 cells per 100 μl in a 96-well 
flat-bottom plate. 1 × 103 to 1 × 104 HPCs and cytokines were added in 100 μl supplemented αMEM. 
FLT3-L (R&D Systems) was used at 200 ng/ml, SCF (R&D Systems) at 40 ng/ml, GM-CSF (Sanofi) 
at 50 ng/ml, TNF-α (R&D Systems) at 10 ng/ml, and LTα1/β2 (Sigma-Aldrich) at 50 ng/ml. Cells 
were cultured for 5–10 days. All cytokines were replenished in full dose on day 5 except for FLT3-L, 
which was used at 100 ng/ml for replenishment.
Immunofluorescence analysis of  CD5 expression. Healthy skin and formalin-fixed psoriasis biopsy spec-
imens from lesional (involved) and adjacent nonlesional skin (uninvolved) were embedded in OCT for 
immunofluorescence staining. Tissue sections were cut into 10-μm sections using the Leica CM 1950. 
Sections were fixed in 4% PFA for 15 minutes at room temperature and washed with PBS containing 
3% bovine serum albumin (BSA) and 10% saponin. The sections were then quenched with 0.5 M gly-
cine for 5 minutes, washed, and blocked with PBS/BSA/saponin for 30 minutes at room temperature. 
Sections were stained overnight with monoclonal mouse anti-human CD5 (5 μg/ml; UCHT2, eBio-
science) or isotype controls, washed, and incubated with anti-mouse Cy3 (3 μg/ml, Jackson Immu-
noresearch) for 2 hours. Samples were then washed and stained with mouse anti-human CD1a-FITC 
(100 mg/ml; NA1/34, DAKO) for 2 hours followed by DAPI for 20 minutes at room temperature. Tis-
sue sections were mounted (ProLong mounting medium, Invitrogen). Images were acquired using an 
Olympus Confocal Microscope FV1000 using Fluoview software. Image analysis was performed using 
ImageJ software (NIH).
DC and T cell cocultures. Naive T cells were isolated using a Pan Naive T cell isolation kit (Miltenyi 
Biotec) according to the manufacturer’s protocol or stained and sorted as CCR7+CD45RA+CD8+ or 
CCR7+CD45RA+CD4+ cells (See Supplemental Table 1). Isolated T cells were labeled with 0.5 μM 
CFSE dye from the CellTrace CFSE cell proliferation kit (Invitrogen), according to the manufacturer’s 
protocol. The CFSE-labeled T cells were then cultured with sorted skin DCs for 7–10 days. Prolifera-
tion was assessed by the percentage of  CFSE-labeling dilution. IL-22, IFN-γ, and granzyme B produc-
tion were assessed by flow cytometry after a short restimulation with PMA (Sigma-Aldrich; 25 ng/
ml) and Ionomycin (Sigma-Aldrich; 1 μM). Alternatively, proliferated cells marked as CFSElo, which 
constitute anything beyond one division (Supplemental Figure 4), were sorted and stimulated overnight 
with anti-CD3 and anti-CD28 mAbs (DYNAL 8 × 105 beads per 3 × 105 cells). Cytokines produced by 
the cells were assessed in the supernatant using a Luminex multiplex bead assay.
Microscopy. Sorted skin DCs were cytospun and stained with Wright-Giemsa stain using a Hema 3 kit 
(Fisher Scientific). Images were acquired using a Leica ×63/1.40 oil objective on a Leica DMIRB micro-
scope with a Leica DFC310 FX camera.
Statistics. Statistical analysis was done using 2-tailed t test. Significance was defined as P < 0.05.
Study approval. The present studies were reviewed and approved by the Washington University School 
of  Medicine in St. Louis Institutional Review Board. Written informed consent was received from each 
participant prior to collection of  psoriatic skin biopsies or blood.
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